179 related articles for article (PubMed ID: 35594723)
1. Assessment of cell-free DNA (cfDNA) concentrations in the perioperative period can predict risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; Cullinane C; Ita M; Corrigan M; O'Leary DP; Redmond HP
Surg Oncol; 2022 Jun; 42():101753. PubMed ID: 35594723
[TBL] [Abstract][Full Text] [Related]
2. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP
Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma.
Long G; Fang T; Su W; Mi X; Zhou L
Scand J Gastroenterol; 2020 Dec; 55(12):1441-1446. PubMed ID: 33119422
[TBL] [Abstract][Full Text] [Related]
4. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
[TBL] [Abstract][Full Text] [Related]
5. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
6. Perioperative cell-free DNA trends predict recurrence of non-metastatic colorectal cancer significantly earlier than CEA trends over the first 2 years post-operatively in stage II and stage III colon cancer.
Fleming CA; Jordan P; O'Leary DP; Corrigan MA; Wang JH; Redmond HP
Int J Colorectal Dis; 2022 May; 37(5):1119-1126. PubMed ID: 35441872
[TBL] [Abstract][Full Text] [Related]
7. Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer.
Ko K; Kananazawa Y; Yamada T; Kakinuma D; Matsuno K; Ando F; Kuriyama S; Matsuda A; Yoshida H
Cancer Med; 2021 Mar; 10(6):2003-2012. PubMed ID: 33641249
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.
Yang J; Cheng L; Zhang J; Chen L; Wang D; Guo X; Ma X
Medicine (Baltimore); 2018 Jul; 97(28):e11417. PubMed ID: 29995790
[TBL] [Abstract][Full Text] [Related]
10. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.
Fettke H; Kwan EM; Bukczynska P; Ng N; Nguyen-Dumont T; Southey MC; Davis ID; Mant A; Parente P; Pezaro C; Hauser C; Azad AA
Eur Urol Focus; 2021 Nov; 7(6):1287-1291. PubMed ID: 32739405
[TBL] [Abstract][Full Text] [Related]
12. Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer.
Peled M; Agassi R; Czeiger D; Ariad S; Riff R; Rosenthal M; Lazarev I; Novack V; Yarza S; Mizrakli Y; Douvdevani A
Sci Rep; 2020 Sep; 10(1):14601. PubMed ID: 32884019
[TBL] [Abstract][Full Text] [Related]
13. Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer: A Feasibility Study.
Ritter M; Paradiso V; Widmer P; Garofoli A; Quagliata L; Eppenberger-Castori S; Soysal SD; Muenst S; Ng CKY; Piscuoglio S; Weber W; Weber WP
Clin Breast Cancer; 2020 Oct; 20(5):413-421.e1. PubMed ID: 32650988
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients.
Khurram I; Khan MU; Ibrahim S; Saleem A; Khan Z; Mubeen M; Khawar A; Ali Q
Sci Rep; 2023 Sep; 13(1):15347. PubMed ID: 37715016
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
Tan G; Chu C; Gui X; Li J; Chen Q
Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
[TBL] [Abstract][Full Text] [Related]
16. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Gómez A; Trullas R; Roldán FL; Ajami T; Moreno D; Rodríguez-Carunchio L; Alcaraz A; Izquierdo L; Mengual L
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233035
[TBL] [Abstract][Full Text] [Related]
17. Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer.
Tanaka K; Yoshida Y; Yamada T; Hayashi T; Shimaoka H; Yoshimura F; Kajitani R; Munechika T; Matsumoto Y; Nagano H; Komono A; Sakamoto R; Nakashima R; Aisu N; Yoshimatsu G; Hasegawa S
Sci Rep; 2021 Jun; 11(1):13263. PubMed ID: 34168268
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight serum cell-free DNA concentration is associated with clinicopathologic indices of poor prognosis in women with uterine cancer.
Gressel GM; Maggi EC; Harmon BE; Ye KQ; Kuo DYS; Dolan SM; Montagna C
J Transl Med; 2020 Aug; 18(1):323. PubMed ID: 32854748
[TBL] [Abstract][Full Text] [Related]
19. Combining
Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
[TBL] [Abstract][Full Text] [Related]
20. PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.
Murillo Carrasco A; Acosta O; Ponce J; Cotrina J; Aguilar A; Araujo J; Rebaza P; Pinto JA; Fujita R; Buleje J
J Clin Lab Anal; 2021 Apr; 35(4):e23720. PubMed ID: 33522650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
